Luther King Capital Management (LKCM)
LGND icon

Luther King Capital Management (LKCM)’s Ligand Pharmaceuticals LGND Stock Holding History

Luther King Capital Management (LKCM)’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-44,163
Closed -$2.63M – 563
2020
Q3 		$2.63M Sell
44,163
-1,114
-2% -$76K 0.02% 228
2020
Q2 		$3.16M Sell
45,277
-2,220
-5% -$141K 0.02% 200
2020
Q1 		$2.15M Sell
47,497
-4,536
-9% -$257K 0.02% 214
2019
Q4 		$3.38M Buy
52,033
+23,844
+85% +$1.59M 0.02% 215
2019
Q3 		$1.75M Sell
28,189
-13,537
-32% -$850K 0.01% 290
2019
Q2 		$2.97M Sell
41,726
-425
-1% -$31.3K 0.02% 225
2019
Q1 		$3.31M Buy
42,151
+10,468
+33% +$793K 0.03% 207
2018
Q4 		$2.68M Sell
31,683
-521
-2% -$55.5K 0.02% 223
2018
Q3 		$5.51M Sell
32,204
-1,411
-4% -$213K 0.04% 181
2018
Q2 		$4.34M Buy
33,615
+3,054
+10% +$341K 0.04% 196
2018
Q1 		$3.15M Buy
+30,561
New +$3.02M 0.03% 230

Other funds holding LGND

William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Luther King Capital Management (LKCM)'s LGND Position: Q4 2020 in Review

Luther King Capital Management (LKCM) sold out of Ligand Pharmaceuticals (LGND) in Q4 2020, closing a stake of 44,163 shares — an estimated $2.63M sold.

Luther King Capital Management (LKCM) first reported a position in LGND in Q1 2018 and held it in 11 quarters. The position peaked at $5.51M in Q3 2018. 242 funds tracked by Wall St. Rank hold LGND as of Q4 2020.

  • Luther King Capital Management (LKCM) reported no remaining Ligand Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Luther King Capital Management (LKCM) sold 44,163 Ligand Pharmaceuticals shares in Q4 2020, an estimated $2.63M.
  • Luther King Capital Management (LKCM) first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 11 quarters.
  • Luther King Capital Management (LKCM)'s Ligand Pharmaceuticals position peaked at $5.51M in Q3 2018.
  • 242 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2020.

Based on Luther King Capital Management (LKCM)'s 13F filing for Q4 2020, filed 10 Feb 2021.